

Bioactive Molecules and Medicinal Plants

Kishan Gopal Ramawat
Jean-Michel Mérillon
(Eds.)

Bioactive Molecules and Medicinal Plants

 Springer

Professor Kishan Gopal Ramawat
Laboratory of Biomolecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur 313001
India
kg_ramawat@yahoo.com

Professor Jean-Michel Mérillon
Groupe d'Etude des Substances
Végétales à Activité Biologique
Laboratoire de Sciences Végétales,
Mycologie et Biotechnologie,
EA 3675 – UFR Pharmacie
Universite Victor Segalen
Bordeaux 2
146 Rue Leo-Saignat
F-33076 Bordeaux cedex
France
jean-michel.merillon@u-bordeaux2.fr

ISBN 978-3-540-74600-3

e-ISBN 978-3-540-74603-4

DOI 10.1007/978-3-540-74603-4

Library of Congress Control Number: 2007933308

© Springer-Verlag Berlin Heidelberg 2008

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broad-casting, reproduction on microfilm or any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: the publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Reproduction, typesetting and production: LE-TEX Jelonek, Schmidt & Vöckler GbR, Leipzig
Cover design: WMXDesign GmbH, Heidelberg

Printed on acid-free paper 21/3180/YL 5 4 3 2 1 0 SPIN 11816423

springer.com

Preface

Use of medicinal plants is as old as human civilization and continuous efforts are being made to improve medicinal plants or produce their products in high amounts through various technologies. About 200,000 natural products of plant origin are known and many more are being identified from higher plants and microorganisms. Some plant-based drugs have been used for centuries and there is no alternative medicine for many drugs, such as cardiac glycosides. However, natural products research was sidelined to pave the way for combinatorial chemistry, which was expected to produce large numbers of synthetic compounds for high-throughput screening (HTS). This line of work has failed to deliver desirable results. Moreover, it is not possible for all pharmaceutical companies and institutions to adopt costly HTS technology. Therefore, medicinal plants and their bioactive molecules are always in demand and are a central point of research. While planning this book, we endeavored to incorporate articles that cover the entire gamut of current medicinal plants research.

The aim of this book was to review the current status of bioactive molecules and medicinal plants research in light of the surge in the demand for herbal medicine. The chapters focus on bioactive molecules (e.g., stilbenes and phytoestrogens) and on medicinal plants as a whole (e.g., *Bacopa monnieri*). We hope that this book will be useful for researchers in academia, industry, and agriculture planning.

Finally, we would like to acknowledge our contributors, who have made serious efforts to ensure the high scientific quality of this book. We also would like to thank our colleagues at Springer.

June 2007

K.G. Ramawat and J.M. Mérillon

About the editors

Professor K.G. Ramawat (born in 1952) received his M.Sc. (1974) and Ph.D. (1978, Plant Biotechnology) from the University of Jodhpur, Jodhpur, India and became a faculty member in January of 1979. He joined M.L. Sukhadia University as an Associate Professor in 1991 and became a Professor in 2001. He served as Head of the Department of Botany (2001–2004), was in charge of the Department of Biotechnology (2003–2004), was a member of the task force on medicinal and aromatic plants at the Department of Biotechnology (Government of India, New Delhi; 2002–2005), and was a coordinator of the UGC-DRS and DST-FIST programs (2002–2007). He did his postdoctoral study at the University of Tours, France (1983–85) and subsequently worked as visiting professor at the University of Tours (1991) and University of Bordeaux 2, France (1995, 1999, 2003, 2006). He visited Poland under the auspices of an INSA-PAN academic exchange program (2005). He has published more than 100 research papers and review articles in reputed journals and books. He has edited two books on the biotechnology of secondary metabolites and of medicinal plants (Scientific Publishers, Enfield, USA). Professor Ramawat has completed several major research projects from UGC, CSIR, ICAR, DBT, and DST, and has supervised the doctoral theses of 16 students. He has been a member of the Plant Tissue Culture Association of India since 1991.

Professor J.M. Mérillon (born in 1953) received his M.Pharm. (1979) and Ph.D. (1984) from the University of Tours, Tours, France. He joined the University of Tours as a faculty member in 1982, became associate professor in 1987, and a full Professor in 1993 at the faculty of Pharmacy, University of Bordeaux 2, Bordeaux, France. He is currently group leader of a “study group on biologically active plant substances” at the Institute of Vine and Wine Sciences, which comprises 20 scientists and research students. He has published more than 80 research papers in internationally recognized journals. He is involved in developing courses and research on phytochemistry and biological properties of compounds from vine and wine in France and has traveled widely as a senior professor. Scientists from several countries are working in his laboratory and his research is supported by funds from the Vinegrowers Association, Ministry of Higher Education and Research, and various private enterprises.

Contents

1 Drug Discovery from Plants

A.A. Salim, Y.-W. Chin and A.D. Kinghorn

1.1	The Role of Plants in Human History	1
1.2	The Role of Plant-Derived Compounds in Drug Development ..	4
1.2.1	Plant Secondary Metabolites as Drug Precursors	4
1.2.2	Plant Secondary Metabolites as Drug Prototypes	6
1.2.3	Plant Secondary Metabolites as Pharmacological Probes	8
1.3	Recent Developments in Drug Discovery from Plants	9
1.3.1	New Plant-Derived Drugs Launched Since 2001	9
1.3.2	Examples of Plant-Derived Compounds Currently Involved in Clinical Trials	11
1.3.3	Plant Extracts Currently Involved in Clinical Trials	15
1.4	Recent Trends and Future Directions	18

2 Grapevine Stilbenes and Their Biological Effects

P. Waffo-Teguo, S. Krisa, T. Richard and J.-M. Mérillon

2.1	Introduction	25
2.2	Epidemiology	26
2.3	Chemistry of Stilbenes	27
2.3.1	Characterisation	27
2.3.1.1	Monomers	27
2.3.1.2	Oligomers	29
2.3.2	Biosynthetic Pathway	32
2.3.3	Distribution in <i>Vitis vinifera</i>	33
2.3.4	Determination of Stilbenes in Wine	33
2.4	Biological and Pharmacological Activities	35
2.4.1	Bioavailability and Metabolism	35
2.4.2	Cardiovascular Protection	39
2.4.2.1	Antioxidant Activity	39
2.4.2.2	Antithrombotic and Vasoprotective Properties	41
2.4.2.3	Biological Activities after Ingestion of Polyphenols or Wine ...	42
2.4.3	Cancer Chemoprevention	43
2.4.4	Neurodegenerative Diseases	46
2.5	Conclusion	49

3 Research into Isoflavonoid Phyto-oestrogens in Plant Cell Cultures

M.T. Luczkiewicz

3.1	Introduction	56
3.2	The Influence of the Basic Experimental Media on the Biosynthesis of Isoflavones in In Vitro Cultures	57
3.3	The Influence of Physical Factors on the Biosynthesis and Accumulation of Isoflavonoids in In Vitro Cultures	59
3.4	The Effect of Technological Procedures on the Biosynthesis and Accumulation of Isoflavonoids in In Vitro Cultures	60
3.4.1	Elicitation	61
3.4.2	Supplementation with Biosynthesis Precursors	70
3.4.3	Biotransformation	71
3.4.4	Genetic Modifications	73
3.5	In Vitro Cultures of Legume Plants Oriented for Selective Production of Phyto-oestrogens	77

4 Secondary Metabolite Production from Plant Cell Cultures: the Success Stories of Rosmarinic Acid and Taxol

S. Kintzios

4.1	Introduction: Cell Factories at the Cross Point	86
4.2	Rosmarinic Acid	87
4.2.1	General Information	87
4.2.2	Historical Development of In Vitro RA Production – a Brief Overview	87
4.2.3	Stimulation of Biosynthetic Pathways Leads to Enhanced RA Accumulation In Vitro	88
4.2.4	Is RA Biosynthesis Growth Dependent?	89
4.2.5	Is RA Accumulation Related to Culture Differentiation?	90
4.2.6	Recent Attempts to Scale Up RA Production	91
4.2.7	RA Production in Immobilized Cell Cultures	92
4.3	Taxol	92
4.3.1	General Information	92
4.3.2	Historical Development of In Vitro Taxol Production – a Brief Overview	93
4.3.3	Stimulation of Biosynthetic Pathways Leads to Enhanced Taxol Accumulation In Vitro	94
4.3.4	Is Taxol Biosynthesis Growth and Differentiation Dependent?	96
4.3.5	Recent Attempts to Scale Up Taxol Production	97
4.3.6	Taxol Production in Immobilized Cell Cultures	97
4.4	Conclusions	98

5 Guggulsterone: a Potent Natural Hypolipidemic Agent from *Commiphora wightii* – Problems, Perseverance, and Prospects
K. G. Ramawat, M. Mathur, S. Dass and S. Suthar

5.1	Introduction	102
5.2	Distribution	102
5.3	Biology	102
5.4	Gum-Resin Production	103
5.5	Chemistry	104
5.6	Methods of Analysis	104
5.6.1	Thin-Layer Chromatography	104
5.6.2	High-Performance Liquid Chromatography	109
5.7	Traditional Therapeutic Uses	109
5.8	Pharmacology	110
5.8.1	Animal and Clinical Trials	110
5.8.2	Mechanism of Action	111
5.8.3	Other Potential Activities	112
5.8.4	Toxicity	113
5.9	Biotechnological Approaches	113
5.9.1	Micropropagation	113
5.9.2	Somatic Embryogenesis	114
5.9.3	Resin Canal Formation	115
5.9.4	Guggulsterone Production	115
5.10	Future Prospects	119

6 *Silybum marianum* (L.) Gaertn: the Source of Silymarin
P. Corchete

6.1	Introduction	124
6.2	Botany	125
6.3	Chemical Composition of <i>S. marianum</i> Fruits	126
6.4	Pharmacology of Silymarin	130
6.4.1	Mechanisms of Action	131
6.4.1.1	Antioxidant Activity	131
6.4.1.2	Effects on Hepatocyte Membranes and Cellular Permeability	131
6.4.1.3	Effects on Receptor Binding of Toxins and Drugs	131
6.4.1.4	Stimulation of Protein Synthesis	132
6.4.1.5	Inhibition of Cell Proliferation in Hepatic Fibrosis	132
6.4.1.6	Anti-inflammatory Activity	132
6.4.2	Pharmacological Applications	132
6.4.2.1	Hepatoprotective Action	132
6.4.2.2	Hypocholesterolemic Action	134
6.4.2.3	Chemopreventive and Anticarcinogenic Effects	134
6.4.2.4	Anti-inflammatory Action	136
6.4.2.5	Other Actions	137

6.4.3	Bioavailability	138
6.4.4	Toxicology	139
6.4.5	Therapeutics	139
6.5	Biotechnology	140
7	The Production of Dianthrones and Phloroglucinol Derivatives in St. John's Wort	
	<i>A. Kirakosyan, D.M. Gibson, and P.B. Kaufman₁</i>	
7.1	Introduction	149
7.2	Dianthrone and Phloroglucinol Derivatives Family of Compounds in <i>Hypericum perforatum</i>	150
7.2.1	Botany of <i>Hypericum</i>	152
7.2.2	Medicinal Uses of Hypericin and Hyperforin	152
7.3	Biotechnology for the Production of Hypericin and Hyperforin	154
7.3.1	Biosynthesis of Hypericin and Hyperforin in Mature Plants ...	154
7.3.2	Plant Cell Biotechnology	156
7.3.3	Influences on Hypericin and Hyperforin Productivity by Other Factors	159
7.3.4	New Directions for Hypericin and Hyperforin Production ...	161
7.4	Conclusions	162
8	Production of Alkaloids in Plant Cell and Tissue Cultures	
	<i>D. Laurain-Mattar</i>	
8.1	Introduction	165
8.2	Correlation Between Organogenesis, Somatic Embryogenesis and Isoquinoline Alkaloid Accumulation	168
8.3	Hairy Roots and Tropane and Morphinan Alkaloid Accumulation	170
8.4	Conclusion and Perspective	171
9	<i>Bacopa monnieri</i>, a Nootropic Drug	
	<i>M. Rajani</i>	
9.1	Introduction	175
9.2	Chemical Constituents	176
9.3	Analysis of Saponins of <i>B. monnieri</i>	184
9.3.1	Pharmacological Studies	184
9.3.2	Clinical Studies	188
9.3.3	Concluding Remarks	189
9.4	Biotechnology and Tissue Culture Studies on <i>B. monniera</i> ...	190

10	Chemical Profiling of <i>Nothapodytes nimmoniana</i> for Camptothecin, an Important Anticancer Alkaloid: Towards the Development of a Sustainable Production System	
	<i>R. Uma Shaanker, B.T. Ramesha, G. Ravikanth, R.P. Gunaga, R. Vasudeva and K.N. Ganeshaiah</i>	
10.1	Introduction	198
10.2	<i>N. nimmoniana</i> : Ecology and Distribution	201
10.3	Basic Patterns of Accumulation of CPT in <i>N. nimmoniana</i>	203
10.4	Chemical Profiling of Populations of <i>N. nimmoniana</i> for CPT ..	204
10.5	Modeling Habitat Suitability for CPT Production	207
10.6	Development of a Sustainable Extraction Approach	209
10.7	Conclusions	210
11	Colchicine – an Overview for Plant Biotechnologists	
	<i>S. Ghosh and S. Jha</i>	
11.1	Introduction	216
11.2	The Alkaloid Colchicine	218
11.3	Toxicity of Colchicine	218
11.4	Biological Effects of Colchicine	219
11.5	Colchicine as a Medicine	222
11.6	Botanical Use of Colchicine	222
11.7	Chemistry of Colchicine	223
11.8	Occurrence	225
11.9	Biotechnological Approaches for the Production of Colchicine	225
11.10	Conclusion	228
12	In Vitro Azadirachtin Production	
	<i>S. Srivastava and A.K. Srivastava</i>	
12.1	Introduction	234
12.2	Chemistry of Azadirachtin	236
12.3	Mode of Action of Azadirachtin	237
12.4	Biosynthetic Pathway for Azadirachtin	238
12.5	Qualitative and Quantitative Analysis of Azadirachtin	238
12.6	Availability of Azadirachtin	242
12.7	Plant Cell/Tissue Culture: an Alternative for Azadirachtin Production	243
12.7.1	Azadirachtin Production from Plant Cell/Tissue Cultures of <i>Azadirachta indica</i>	243
12.7.2	Yield Improvement Strategies	244
12.7.2.1	Strain Improvement and Selection	245
12.7.2.2	Media Compositions and Culture Conditions	245

12.7.2.3	Application of Elicitors, Precursors and Permeabilising Agents	246
12.7.2.4	Genetic Engineering Approach	247
12.7.2.5	Somatic Embryogenesis and Regeneration	248
12.7.2.6	Two-Phase (Stage) Systems	248
12.7.2.7	Immobilisation	248
12.8	Stability of Azadirachtin	249
12.9	Scale-up of In Vitro Azadirachtin Production	249
12.10	Conclusion	250

13 Arabinogalactan Protein and Arabinogalactan: Biomolecules with Biotechnological and Therapeutic Potential

A. Pal

13.1	Introduction	256
13.2	Biological Activities of AGP	259
13.3	Role of AGPs in Reproductive Organ Development	261
13.4	Signaling Role of AGP	262
13.5	Abiotic Stress Tolerance Conferred by AGP	263
13.6	Probable Role in PCD	263
13.7	Commercial Uses of Gum Arabic	264
13.8	AG as Dietary Fiber and Prebiotics	264
13.9	AG as Immunomodulators and Immunity Enhancers	265
13.10	Echinacea-AG as a Nutraceutical	266
13.11	Other Uses of AG	266
13.12	Scope of Exploiting the Potentials of AGP and AG in Plant Biotechnology and Therapeutics	267
13.13	Concluding Remarks	267

14 Hairy Roots: a Powerful Tool for Plant Biotechnological Advances

S. Guillon, J. Trémouillaux-Guiller, P.K. Pati, and P. Gantet

14.1	Introduction	272
14.2	Hairy Roots Are on the Way to towards an Experimental Model	272
14.3	Improvement in the Productivity of Hairy Roots: Biotic and Abiotic Treatments or Metabolite Trapping	275
14.4	Potential Discovery of Metabolic Genes from Transcriptome Analysis of T-DNA Activation Tagging or Elicited Hairy Roots	277
14.5	RNA Silencing via Hairy Root: a Powerful Tool for Loss-of-Function Analyses of Genes	277
14.6	Metabolic Engineering of the Hairy Root System	278
14.7	Hairy Roots: A Novel System for Molecular Farming	279
14.8	Phytoremediation Process for Cleaning up the Environment and More Knowledge on Root Adsorption	279
14.9	Scale up and Technological Integration into Industry	280

14.10	Perspectives	281
15	Hairy Roots of <i>Catharanthus roseus</i>: Efficient Routes to Monomeric Indole Alkaloid Production <i>S. Guillon, P. Gantet, M. Thiersault, M. Rideau and J. Trémouillaux-Guiller</i>	
15.1	Introduction	286
15.2	Materials and Methods	286
15.2.1	Bacterial Strain	286
15.2.2	Plant Material	287
15.2.3	Hairy Root Induction	287
15.2.4	Liquid Hairy Root Culture	287
15.2.5	Methyl Jasmonate Treatment	287
15.2.6	Alkaloid Identification by Ceric Ammonium Sulphate Reagent	288
15.2.7	Serpentine and Ajmalicine Content Determination by Spectrofluorometry	288
15.2.8	Catharanthine Content Determination by High-Performance Liquid Chromatography Analysis	288
15.2.9	Statistical Analysis	289
15.3	Results and Discussion	289
15.3.1	Genetic Transformation of <i>Catharanthus</i> Leaves	289
15.3.2	Alkaloid Profiles	291
15.3.3	Alkaloid Contents	292
15.4	Conclusion	294
16	Roseroot (<i>Rhodiola rosea</i> L.): Effect of Internal and External Factors on Accumulation of Biologically Active Compounds <i>Z. Węglarz, J.L. Przybył and A. Geszprych</i>	
16.1	Introduction	298
16.2	Plant Characteristics	298
16.3	Intraspecific Variability	300
16.3.1	Distribution of Phenolic Compounds in Rhizomes and Roots	300
16.3.2	Quality of Raw Material of Different Origin	303
16.3.3	Individual Variation	304
16.4	Accumulation of Biomass and Biologically Active Compounds in the Underground Organs of Roseroot During Plant Development	305
16.5	Effect of Ecological Factors on the Accumulation of Biomass and Biologically Active Compounds in the Underground Organs of Roseroot	308
16.6	Effect of Post-harvest Treatment on the Quality of Raw Material and Extracts	310

17 Apoptosis and Plant-Derived Pharmaceuticals*L.F. Brisson*

17.1	Introduction	317
17.1.1	Molecular Regulation of Apoptosis	317
17.2	Plant Antitumoral Substances	318
17.2.1	Plant Substances	318
17.2.2	Chemotherapeutic Drugs	319
17.2.2.1	Taxanes	319
17.2.2.2	Vinca Alkaloids	320
17.2.3	Chemopreventive Agents: Catechin and its Derivatives	321
17.3	Conclusion	322

18 The Indian Herbal Drugs Scenario in Global Perspectives*K.G. Ramawat and S. Goyal*

18.1	Introduction	325
18.2	Indian System of Medicine	328
18.3	World-Wide Use of Medicinal Aromatic Plants	336
18.4	Supply and Demand of Medicinal Plants	337
18.5	Medicinal Plant Biodiversity	338
18.6	Traditional Medicine in Healthcare	340
18.7	Indian Pharmaceutical Industries	341
18.8	Quality of Herbal Drugs	342
18.9	Concluding Remarks	343

19 Phytochemical Standardization of Herbal Drugs and Polyherbal Formulations*M. Rajani and N.S. Kanaki*

19.1	Introduction	349
19.1.1	Herbal drugs	349
19.1.2	Trade Scenario	350
19.1.3	Bottlenecks and Steps to be Taken	350
19.1.4	Strategy	351
19.1.5	Status of Herbal Drugs in Pharmacopoeias	351
19.1.5.1	Official	352
19.1.5.2	Others	352
19.2	Phytochemical Standardization	352
19.2.1	Sample Preparation	353
19.2.2	Preliminary Screening for Chemical Groups and Quantification of Chemical Groups	354
19.2.3	Phytochemical Profiles – Fingerprinting	354
19.2.3.1	Multiple Marker-Based Fingerprinting	355

19.2.4	Marker Compound Analysis	357
19.2.4.1	Marker Compounds	357
19.2.4.2	Quantification of Marker Compounds	357
19.2.5	Multiple Marker-Based Evaluation	358
19.2.6	Polyherbal Formulations	359
19.2.7	Hyphenated Techniques	361
19.2.8	Reference Compounds	364
19.3	Some Examples	364
19.3.1	Raw Material	364
19.3.1.1	Ammoniacum Gum	364
19.3.1.2	<i>Cinchona officinalis</i> Stem Bark	365
19.3.2	Formulation	366
19.3.2.1	Chandraprabhavati	366
19.4	Conclusion	366
 Subject Index		 371

List of Contributors

Editors

K.G. Ramawat

Laboratory of Biomolecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur 313001
India
kg_ramawat@yahoo.com

Jean-Michel Mérillon

Groupe d'Etude des Substances
Végétales à Activité Biologique
Laboratoire de Sciences Végétales
Mycologie et Biotechnologie
EA 3675 – UFR Pharmacie
Université Victor Segalen
Bordeaux 2
146 Rue Leo-Saignat
F-33076 Bordeaux cedex
France
jean-michel.merillon@u-bordeaux2.fr

Authors

Louise F. Brisson

Department of Biochemistry
and Microbiology, Research in Health
and Life Science Building
Laval University Quebec
Quebec
Canada
G1K 7P4
louise.brisson@bcm.ulaval.ca

S. Dass

Laboratory of Bio-Molecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur-313001
India

A. Douglas Kinghorn

College of Pharmacy
The Ohio State University
500 West 12th Avenue
Columbus
OH 43210-1291
USA
kinghorn.4@osu.edu

Young-Won Chin

College of Pharmacy
The Ohio State University
500 West 12th Avenue
Columbus
OH 43210-1291
USA

Purificación Corchete

Department of Plant Physiology
Faculty of Pharmacy
University of Salamanca
37007-Salamanca
Spain
corchpu@usal.es

K.N. Ganeshaiiah

Department of Genetics and Plant
Breeding
University of Agricultural Sciences
GKVK Campus
Bangalore 560065
India

Pascal Gantet

Université Montpellier 2
UMR PIA 1096
Laboratoire de Biochimie
et de Physiologie Végétales
Place Eugène Bataillon
Bat 15 CC 002
34095 Montpellier cedex 5
France

A. Geszprych

Department of Vegetable
and Medicinal Plants
Warsaw Agricultural University
Nowoursynowska 159
02-776 Warsaw
Poland

Seemanti Ghosh

Centre of Advanced Study in
Cell and Chromosome Research
Department of Botany
University of Calcutta
35 Ballygunge Circular Road
Calcutta 700019
India

Donna M. Gibson

USDA Agricultural Research Service
Plant Protection Research Unit
U.S. Plant, Soil, and Nutrition
Laboratory
Tower Road
Ithaca
NY 14583
USA

Shaily Goyal

Laboratory of Biomolecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur 313001
India

Stéphanie Guillon

UPRES EA 2106 “Biomolécules
et Biotechnologies Végétales”
Université François Rabelais
UFR des Sciences Pharmaceutiques
Parc de Grandmont
37200 Tours
France

R. Gunaga

Department of Forest Biology
College of Forestry
Sirsi 581401
India

Sumita Jha

Centre of Advanced Study in
Cell and Chromosome Research
Department of Botany
University of Calcutta
35 Ballygunge Circular Road
Calcutta 700019
India
sjbot@caluniv.ac.in

Peter B. Kaufman

Department of Cardiac Surgery
University of Michigan
1150 West
Medical Center Dr, Ann Arbor
Michigan 48109-0686
USA

Niranjan S. Kanaki

B.V. Patel Pharmaceutical Education
and Research Development (PERD)
Centre
Thaltej
Ahmedabad – 380 054
Gujarat
India

Spiridon Kintzios

Laboratory of Plant Physiology
Faculty of Agricultural
Biotechnology
Agricultural University of Athens
Iera Odos 75
11855 Athens
Greece
spiroskintzios@usa.net

Ara Kirakosyan

Department of Cardiac Surgery
University of Michigan
1150 West
Medical Center Dr, Ann Arbor
Michigan 48109-0686
USA
akirakos@umich.edu

Pratap Kumar Pati

Department of Botanical
and Environmental Sciences
Guru Nanak Dev University
Amritsar-143 005
India

Stéphanie Krisa

Groupe d'Etude des Substances
Végétales à Activité Biologique
Laboratoire de Sciences Végétales
Mycologie et Biotechnologie
EA 3675 – UFR Pharmacie
Universite Victor Segalen
Bordeaux 2
146 Rue Leo-Saignat
F-33076 Bordeaux cedex
France

Dominique Laurain-Mattar

Groupe S.U.C.R.E.S.
U.M.R. 7565 C.N.R.S.
Nancy-Université
BP 239
54506 Nancy-Vandoeuvre
France
*dominique.laurain-mattar@pharma.
uhp-nancy.fr*

M. Mathur

Laboratory of Biomolecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur-313001
India

Professor Jean-Michel Mérillon

Groupe d'Etude des Substances
Végétales à Activité Biologique
Laboratoire de Sciences Végétales
Mycologie et Biotechnologie
EA 3675 – UFR Pharmacie
Universite Victor Segalen
Bordeaux 2
146 Rue Leo-Saignat
F-33076 Bordeaux cedex
France
jean-michel.merillon@u-bordeaux2.fr

Amita Pal

Plant Molecular and Cellular
Genetics
P 1/12 CIT Scheme VIIM
Kolkata – 700054
India
amita_pal@yahoo.com

J.L. Przybył

Department of Vegetable
and Medicinal Plants
Warsaw Agricultural University
Nowoursynowska 159
02-776 Warsaw
Poland

M. Rajani

B.V. Patel Pharmaceutical Education
and Research Development (PERD)
Centre
Thaltej
Ahmedabad – 380 054
Gujarat
India
rajanivenkat@hotmail.com

Professor K.G. Ramawat

Laboratory of Biomolecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur 313001
India
kg_ramawat@yahoo.com

B.T. Ramesha

Department of Crop Physiology
University of Agricultural Sciences
GKVK Campus
Bangalore 560065
India

G. Ravikanth

School of Ecology and Conservation
University of Agricultural Sciences
GKVK Campus
Bangalore 560065
India

Tristan Richard

Groupe d'Etude des Substances
Végétales à Activité Biologique
Laboratoire de Biophysique
EA 3675 – UFR Pharmacie
Université Victor Segalen
Bordeaux 2
146 Rue Leo-Saignat
F-33076 Bordeaux cedex
France

Marc Rideau

UPRES EA 2106 “Biomolécules
et Biotechnologies Végétales”
Université François Rabelais
UFR des Sciences Pharmaceutiques
Parc de Grandmont
37200 Tours
France

Angela A. Salim

College of Pharmacy
The Ohio State University
500 West 12th Avenue
Columbus
OH 43210-1291
USA

S. Suthar

Laboratory of Biomolecular
Technology, Department of Botany
M.L. Sukhadia University
Udaipur-313001
India

R. Uma Shaanker

Department of Crop Physiology
University of Agricultural Sciences
GKVK Campus
Bangalore 560065
India
rus@vsnl.com

Martine Thiersault

UPRES EA 2106 “Biomolécules
et Biotechnologies Végétales”
Université François Rabelais
UFR des Sciences Pharmaceutiques
Parc de Grandmont
37200 Tours
France

Jocelyne Trémouillaux-Guiller

UPRES EA 2106 “Biomolécules
et Biotechnologies Végétales”
Université François Rabelais
UFR des Sciences Pharmaceutiques
Parc de Grandmont
37200 Tours
France
j.tremouillaux@telez.fr

R. Vasudeva

Ashoka Trust for Research in
Ecology and the Environment #659
5th A Main
Hebbal
Bangalore 560024
India

Pierre Waffo-Teguo

Groupe d'Etude des Substances
Végétales à Activité Biologique
Laboratoire de Sciences Végétales
Mycologie et Biotechnologie
EA 3675 – UFR Pharmacie
Universite Victor Segalen
Bordeaux 2
146 Rue Leo-Saignat
F-33076 Bordeaux cedex
France

Z. Węglarz

Department of Vegetable
and Medicinal Plants
Warsaw Agricultural University
Nowoursynowska 159
02-776 Warsaw
Poland
weglarz@alpha.sggw.waw.pl

Chapter 1

Drug Discovery from Plants

A.A. Salim, Y.-W. Chin and A.D. Kinghorn (✉)

Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy,
The Ohio State University, Columbus, OH 43210, USA, e-mail: kinghorn.4@osu.edu

Abstract Many plant-derived compounds have been used as drugs, either in their original or semi-synthetic form. Plant secondary metabolites can also serve as drug precursors, drug prototypes, and pharmacological probes. Recent developments in drug discovery from plants, including information on approved drugs and compounds now in clinical trials, are presented. There are also several plant extracts or “phytomedicines” in clinical trials for the treatment of various diseases. In the future, plant-derived compounds will still be an essential aspect of the therapeutic array of medicines available to the physician, particularly with the availability of new hyphenated analytical methods such as LC-NMR-MS and LC-SPE-NMR to accelerate their future discovery.

Keywords Natural products, Plant-derived drugs, Drug discovery, Drug development, Drug precursors, Drug prototypes, Pharmacological probes, New therapeutic agents, Clinical trials, Accelerated discovery techniques

1.1 The Role of Plants in Human History

Over the centuries humans have relied on plants for basic needs such as food, clothing, and shelter, all produced or manufactured from plant matrices (leaves, woods, fibers) and storage parts (fruits, tubers). Plants have also been utilized for additional purposes, namely as arrow and dart poisons for hunting, poisons for murder, hallucinogens used for ritualistic purposes, stimulants for endurance, and hunger suppression, as well as inebriants and medicines. The plant chemicals used for these latter purposes are largely the secondary metabolites, which are derived biosynthetically from plant primary metabolites (e.g., carbohydrates, amino acids, and lipids) and are not directly involved in the growth, development, or reproduction of plants. These secondary metabolites can be classified into several groups according to their chemical classes, such as alkaloids, terpenoids, and phenolics [1].

Arrow and dart poisons have been used by indigenous people in certain parts of the world with the principal ingredients derived from the genera *Aconitum* (Ranunculaceae), *Akocanthera* (Apocynaceae), *Antiaris* (Moraceae), *Chondrodendron* (Menispermaceae), *Strophanthus* (Apocynaceae), and *Strychnos* (Loganiaceae) [2]. Most compounds responsible for the potency of arrow and dart poisons belong to three plant chemical groups, namely the alkaloids (e.g., strychnine from *Strychnos* species), cardiac glycosides (e.g., ouabain from *Strophanthus* species), and saponins (e.g., a monodesmoside glucoside from *Clematis* species) [2].

In some cultures, toxic plant extracts were also used for murder and “trials by ordeal,” where a person accused of a crime was given a noxious brew, and it was believed that if innocent, this suspect would survive this ordeal. Some of the plants well-documented for murder are henbane (*Hyoscyamus niger* L.), mandrake (*Mandragora officinarum* L.), deadly nightshade (*Atropa belladonna* L.), and some *Datura* species, all of which belong to the family Solanaceae [3]. Calabar bean (*Physostigma venenosum* Balf.) was famous for its use in trials by ordeal by people who lived on the Calabar Coast, West Africa [3]. Certain plants formerly used for arrow poisons, such as several *Aconitum* species, have also been used as medicines at lower dosages, for their analgesic and anti-inflammatory properties [4]. In fact, many compounds isolated from poisonous plants were later developed as therapeutic drugs, due to their desirable pharmacological actions [5, 6].

The use of hallucinogens in the past was usually associated with magic and ritual. However, these hallucinogens have been exploited as recreational drugs and accordingly may lead to habituation problems. Several well-recognized plants that contain hallucinogenic or psychoactive substances (the compound names are given in parentheses) include *Banisteriopsis caapi* (Spruce ex Griseb.) Morton (*N,N*-dimethyltryptamine), *Cannabis sativa* L. (Δ^9 -*trans*-tetrahydrocannabinol), *Datura* species (scopolamine), *Erythroxylum coca* Lam. (cocaine), *Lophophora williamsii* (Salm-Dyck) J.M. Coult. (mescaline), *Papaver somniferum* L. (morphine), and *Salvia divinorum* Epling & Játiva (salvinorin A) [7, 8]. Several of these plants are also used as drugs due to their desired pharmacological activities, and some of the constituents of these plants have been developed into modern medicines, either in the natural form or as lead compounds subjected to optimization by synthetic organic chemistry [5, 6].

Plants have also been used in the production of stimulant beverages (e.g., tea, coffee, cocoa, and cola) and inebriants or intoxicants (e.g., wine, beer, kava) in many cultures since ancient times, and this trend continues till today. Tea (*Camellia sinensis* Kuntze) was first consumed in ancient China (the earliest reference is around CE 350), while coffee (*Coffea arabica* L.) was initially cultivated in Yemen for commercial purposes in the 9th century [3]. The Aztecs used to consume bitter beverages containing raw cocoa beans (*Theobroma cacao* L.), red peppers, and various herbs [3]. Nowadays, tea, coffee, and cocoa are important commodities and their consumption has spread worldwide. The active components of these stimulants are methylated xanthine derivatives, namely caffeine, theophylline, and theobromine, which are the main constituents of coffee, tea, and cocoa, respectively [9].

The most popular inebriants in society today are wine, beer, and liquor made from the fermentation of fruits and cereals. Wine was first fermented about 6000–8000 years ago in the Middle East, while the first beer was brewed around 5000–6000 BCE by the Babylonians [3]. The intoxicating ingredient of these drinks is ethanol, a by-product of bacterial fermentation, rather than secondary plant metabolites. Recent studies have shown that a low to moderate consumption of red wine is associated with reduction of mortality due to cardiovascular disease and cancer [10]. This health benefit has been suggested to be due to the presence of resveratrol, a hydroxylated stilbenoid found in the skin of grapes [11]. Kava, a beverage made from the root of *Piper methysticum* Roxb., has been a popular intoxicating beverage in Polynesia for centuries [3]. Kava is not normally consumed in this manner in the Western world, but has gained popularity as a botanical dietary supplement to ease the symptoms of stress, anxiety, and depression [12]. A study has shown that the anxiolytic activity of kava extract may be mediated in part by the kavalactone, dihydrokavain [13]. The consumption of kava has been associated with liver toxicity, although this is somewhat controversial. Recently, a study has shown that the alkaloid pipermethystine, found mostly in the leaves and stems of *Piper methysticum*, may be responsible for this toxicity [14].

Plants have formed the basis of sophisticated traditional medicine (TM) practices that have been used for thousands of years by people in China, India, and many other countries [9]. Some of the earliest records of the usage of plants as drugs are found in the Artharvaveda, which is the basis for Ayurvedic medicine in India (dating back to 2000 BCE), the clay tablets in Mesopotamia (1700 BCE), and the Eber Papyrus in Egypt (1550 BCE) [9]. Other famous literature sources on medicinal plant include “De Materia Medica,” written by Dioscorides between CE 60 and 78, and “Pen Ts’ao Ching Classic of Materia Medica” (written around 200 CE) [9].

Before the realization that pharmacologically active compounds present in medicinal plants are responsible for their efficacy, the “doctrine of signatures” was often used to identify plants for treating diseases. For example, goldenrod with a yellow hue was used to cure jaundice, red-colored herbs were used to treat blood diseases, liverworts were used for liver diseases, pileworts for hemorrhoids, and toothworts for toothache [9]. In 1805, morphine became the first pharmacologically active compound to be isolated in pure form from a plant, although its structure was not elucidated until 1923 [9]. The 19th century marked the isolation of numerous alkaloids from plants (species in parentheses) used as drugs, namely, atropine (*Atropa belladonna*), caffeine (*Coffea arabica*), cocaine (*Erythroxylum coca*), ephedrine (*Ephedra* species), morphine and codeine (*Papaver somniferum*), pilocarpine (*Pilocarpus jaborandi* Holmes), physostigmine (*Physostigma venenosum*), quinine (*Cinchona cordifolia* Mutis ex Humb.), salicin (*Salix* species), theobromine (*Theobroma cacao*), theophylline (*Camellia sinensis*), and (+)-tubocurarine (*Chondodendron tomentosum* Ruiz & Pav.) [9]. Following these discoveries, bioactive secondary metabolites from plants were later utilized more widely as medicines, both in their original and modified forms [5, 6].

The correlation between the ethnomedical usage of medicinal plants and modern medicines discovered from those plants has been studied by Fabricant and Farnsworth [15]. Based on their analysis, 88 single chemical entities isolated from 72 medicinal plants have been introduced into modern therapy, many of which have the same or a similar therapeutic purpose as their original ethnomedical use [15]. Some of these plant-derived compounds, such as atropine (anticholinergic), codeine (cough suppressant), colchicine (antigout), ephedrine (bronchodilator), morphine (analgesic), pilocarpine (parasympathomimetic), and physostigmine (cholinesterase inhibitor) are still being used widely as single-agent or combination formulations in prescription drugs [5].

Nowadays, plants are still important sources of medicines, especially in developing countries that still use plant-based TM for their healthcare. In 1985, it was estimated in the Bulletin of the World Health Organization (WHO) that around 80% of the world's population relied on medicinal plants as their primary healthcare source [16]. Even though a more recent figure is not available, the WHO has estimated that up to 80% of the population in Africa and the majority of the populations in Asia and Latin America still use TM for their primary healthcare needs [17]. In industrialized countries, plant-based traditional medicines or phytotherapeutics are often termed complementary or alternative medicine (CAM), and their use has increased steadily over the last 10 years. In the USA alone, the total estimated "herbal" sales for 2005 was \$4.4 billion, a significant increase from \$2.5 billion in 1995 [18]. However, such "botanical dietary supplements" are regulated as foods rather than drugs by the United States Food and Drug Administration (US FDA).

1.2 The Role of Plant-Derived Compounds in Drug Development


Despite the recent interest in drug discovery by molecular modeling, combinatorial chemistry, and other synthetic chemistry methods, natural-product-derived compounds are still proving to be an invaluable source of medicines for humans. The importance of plants in modern medicine has been discussed in recent reviews and reports [19–22]. Other than the direct usage of plant secondary metabolites in their original forms as drugs, these compounds can also be used as drug precursors, templates for synthetic modification, and pharmacological probes, all of which will be discussed briefly in turn in this section.

1.2.1 Plant Secondary Metabolites as Drug Precursors

Some natural products obtained from plants can be used as small-molecule drug precursors, which can be converted into the compound of interest by chemical

modification or fermentation methods. The semisynthetic approach is usually used to resolve the shortage of supply due to the low yield of compounds from plants and/or the high cost of total synthesis. For compounds with complex structures and many chiral centers, protracted methods may be needed for their synthesis, and thus these methods would not be feasible economically. The following examples indicate that some secondary metabolites from plants are useful drug precursors, although they are not necessarily pharmacologically active in their original naturally occurring forms.


Cropping of the bark of the slow-growing Pacific yew tree, *Taxus brevifolia* Nutt., is not a feasible method to provide sufficient amounts of the antitumor drug paclitaxel (1, Taxol) to meet the market demand (paclitaxel was originally isolated in only 0.014% w/w yield from the bark of *Taxus brevifolia*) [23]. Even though this compound can be produced by total synthesis, this has proven to be inefficient in affording large quantities of paclitaxel [24, 25]. Fortunately, 10-deacetylbaccatin III (2) can be isolated in relatively large amounts from the needles of other related yew species, such as *Taxus baccata* L. (a renewable resource), and can be converted chemically in several steps into paclitaxel [26, 27]. During the period 1993–2002, the main pharmaceutical manufacturer, Bristol-Myers Squibb, adopted the semisynthetic method developed by the Holton research group to produce paclitaxel from 10-deacetylbaccatin III [27, 28]. Since 2002, Bristol-Myers Squibb has produced paclitaxel using a plant cell culture method, which will be mentioned in section 1.4 of this chapter [29].




Diosgenin (3), a steroidal sapogenin obtained from the tubers of various *Dioscorea* species that grow in Mexico and Central America, can be converted chemically in several steps into progesterone (4), a hormone that can be used as a female oral contraceptive [30]. Originally, progesterone was isolated from sow ovaries with a very low yield (20 mg from 625 kg of ovaries), and later was synthesized from cholesterol with very low efficiency [31]. Progesterone is also a key intermediate for the production of cortisone (5), an important anti-inflammatory drug. Progesterone can be converted into 11 α -hydroxyprogesterone (6) by microbial hydroxylation at C-11, followed by chemical reactions, to produce

been developed in the process of developing such derivatives. In the following examples, podophyllotoxin, camptothecin, and guanidine have been selected as drug prototypes with analogs having the same pharmacological action as the parent compound, while atropine is a drug prototype that has furnished many analogs that have additional pharmacological properties.

Several antineoplastic compounds isolated from plants, such as podophyllotoxin (**9**) and camptothecin (**10**), are too toxic or not water soluble enough for clinical application, and analogs with higher therapeutic indices such as etoposide (**11**, Vepesid) and topotecan (**12**, Hycamtin) have been developed in consequence [40, 41]. Due to their unique modes of anticancer activities, there is much interest in the clinical development of further derivatives of paclitaxel (**1**) and camptothecin (**10**) as anticancer therapeutic drugs [28, 41–43]. According to a recent review, of the 2255 cancer clinical trials recorded as of August 2003, 310 (or 13.7%) and 120 (or 5.4%) of the trials involved taxane- and camptothecin-derived drugs, respectively [43]. In 2002, it was estimated that the combined sales of paclitaxel and docetaxel (both taxanes), and topotecan and irinotecan (both based on the parent molecule camptothecin) constituted over 30% of the total global sales of cytotoxic drugs [44].




Guanidine (**13**) is a natural product with good hypoglycemic activity isolated from *Galega officinalis* L., but is too toxic for clinical use [45]. Many derivatives of guanidine have been synthesized, and metformin (dimethylbiguanide) (**14**) was later found to be clinically suitable for treatment of type II diabetes [46].



Atropine (**15**) is an artifact of the tropane alkaloid (–)-hyoscyamine, which racemizes during the extraction process from its plant of origin (*Atropa belladonna*). Atropine is a competitive antagonist of muscarinic acetylcholine


receptors (antimuscarinic agent). Atropine is sometimes used in the ophthalmology area as a mydriatic agent, and has additional therapeutic uses as an antispasmodic. It is also used as a premedication for anesthesia, to decrease bronchial and salivary secretions, and to block the bradycardia (low heart rate) associated with the administration of anesthetic drugs [5]. Biological and physiological studies of a large number of synthetic atropine analogs have led to the introduction of new drugs with different therapeutic applications than the parent compound. Examples of drugs derived from the basic atropine skeleton include droperidol (**16**, antipsychotic), ipratropium bromide (**17**, bronchodilator for the treatment of asthma), loperamide (**18**, antidiarrheal), methadone (**19**, a morphine substitute for addicts), and pethidine (**20**, analgesic) [5].




1.2.3 Plant Secondary Metabolites as Pharmacological Probes

In addition to their direct contribution as drugs or drug prototypes to cure human disease, secondary metabolites of plant origin, such as phorbol esters and genistein, can be used as “pharmacological probes.” Pharmacological probes help researchers to understand the mechanism of action of intracellular signal transductions and biological mechanisms related to human disease, which can aid the design of better drugs.

Genistein (**21**), an isoflavone found naturally in soybean (*Glycine max* Merr.), is an inhibitor of various protein tyrosine kinases (PTK), which are essential enzymes involved in intracellular signal transduction [47]. Genistein has been used to probe the interaction between PTK and cyclic nucleotide-gated (CNG) channels, which are important in mammalian olfactory and visual systems [48, 49]. By observing the effect of genistein on the CNG channels containing either homomeric or heteromeric subunits, specific subunits containing binding sites for PTKs can be identified [48]. Furthermore, the mechanism of inhibition of the CNG channels by PTKs has been studied with the aid of genistein as a probe [49].



Phorbol is a tetracyclic diterpenoid plant secondary metabolite isolated as a hydrolysis product of croton oil from the seeds of *Croton tiglium* L. [50]. Various 12,13-diester of phorbol have the capacity to act as tumor promoters, due in part to their role as protein kinase C (PKC) activators [51–53]. The most abundant phorbol ester derivative of croton oil, 12-*O*-tetradecanoylphorbol-13-acetate (TPA) (**22**), has been used in biomedical research in standard laboratory models of carcinogenesis promotion [54–56].



1.3 Recent Developments in Drug Discovery from Plants

Despite the large number of drugs derived from total synthesis, plant-derived natural products still contribute to the overall total number of new chemical entities (NCE) that continue to be launched to the market. Several reviews on drug discovery and development from natural sources (plants, marine fauna, microbes) have been published recently [42, 57–59]. The following sections will cover specifically the plant-derived drugs newly launched since 2001 and examples of some plant-derived compounds currently in clinical trials.


1.3.1 New Plant-Derived Drugs Launched Since 2001

In the past 6 years, five new drugs derived from natural products, namely, apomorphine hydrochloride, galanthamine hydrobromide, nitisinone, tiotropium bromide, and varenicline, have been approved by the US FDA. The following is a brief description of each drug and their therapeutic use.


Galantamine (**23**, Razadyne, Reminyl, Nivalin) was first marketed in 2001 in the USA for the symptomatic treatment of patients with early-onset Alzheimer's

disease [58]. Galantamine (also known as galanthamine) is an alkaloid that was initially isolated from the snowdrop (*Galanthus woronowii* Losinsk.) in the early 1950s, and has since been found in other plants in the family Amaryllidaceae [60]. Galantamine slows the process of neurological degeneration by inhibiting acetylcholinesterase as well as binding to and modulating the nicotinic acetylcholine receptor [60, 61]. Due to the limited availability of the plants of origin of this compound, galantamine is now produced by total synthesis.


Nitisinone (**24**, Orfadin) was approved by the FDA in 2002 for the treatment of hereditary tyrosinemia type 1 (HT-1) [58]. HT-1 is a rare pediatric disease caused by a deficiency of fumaryl acetoacetate hydrolase (FAH), an enzyme essential in the tyrosine catabolism pathway. FAH deficiency leads to the accumulation of toxic substances in the body, resulting in liver and kidney damage [62]. Nitisinone is a derivative of leptospermone (**25**), a new class of herbicide from the bottlebrush plant [*Callistemon citrinus* (Curtis) Skeels]. Both nitisinone and leptospermone inhibit 4-hydroxyphenyl pyruvate dioxygenase (HPPD), the enzyme involved in plastoquinone and tocopherol biosynthesis in plants [63]. In humans, inhibition of HPPD prevents tyrosine catabolism, leading to the accumulation of tyrosine metabolites, 4-hydroxyphenyl pyruvic acid and 4-hydroxyphenyl lactic acid, which can be excreted through the urine [64].




Apomorphine (**26**, Apokyn) was approved by the FDA in 2004 as an injectable drug for the symptomatic treatment for Parkinson's disease patients during episodes of "hypomobility" (e.g., persons unable to move or to perform daily activities) [65]. Apomorphine is a synthetic derivative of morphine (**27**), but unlike morphine, apomorphine does not have opioid analgesic properties, and instead is a short-acting dopamine D₁ and D₂ receptor agonist [66].



Tiotropium bromide (**28**, Spiriva), an atropine analog, was approved by the FDA in 2005 for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [67].



Varenicline (**29**, Chantix), based on the plant quinolizidine alkaloid, cytisine (**30**), has been approved by the FDA since 2006 as an aid to smoking cessation [68–70]. Cytisine (**30**), an alkaloid isolated from *Cytisus laburnum* L., has been used to treat tobacco dependence in Eastern Europe (Bulgaria, Germany, Poland, and Russia) for the last 40 years [71]. Cigarette smoking has been linked to several diseases including cardiovascular disease, COPD, many cancers (particularly lung, mouth, and esophageal), and pregnancy-related complications. Varenicline (**29**) is a partial agonist with a high affinity for the $\alpha_4\beta_2$ nicotinic acetylcholine receptor, and is a full agonist at α_7 neuronal nicotinic receptors [70].



1.3.2 Examples of Plant-Derived Compounds Currently Involved in Clinical Trials

Although relatively few plant-derived drugs have been launched onto the market the last 6 years, many plant-derived compounds are currently undergoing clinical trial for the potential treatment of various diseases. The majority of such drugs under clinical development are in the oncological area, including new analogs of known anticancer drugs based on the camptothecin-, taxane-, podophyllotoxin-, or vinblastine-type skeletons [42]. Examples of compounds with carbon skeletons different from the existing plant-derived drugs used in cancer chemotherapy will be discussed below, namely, betulinic acid, ceflatonine (homoharringtonine), combretastatin A4 phosphate, ingenol-3-angelate, phenoxodiol, and protopanaxadiol. In the antiviral area, bevirimat and celtosivir are currently undergoing clinical trials for the treatment of human immunodeficiency viral (HIV) and hepatitis C viral (HCV) infections, respectively. Capsaicin is in clinical trial for the treatment of severe postoperative pain, while huperzine is being developed for the treatment of Alzheimer's disease.